Nivolumab+AVD Improves Survival in Advanced Classic Hodgkin’s Lymphoma Compared to Brentuximab Vedotin+AVD
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP. 2. Progression-free survival at 48 months was significantly greater in ...
Click to read this study in the Journal of Clinical Oncology.
Click to read the study in JAMA Dermatology.
1. Older age, progressive disease status, diagnosis of acute myeloid leukemia, non-Hodgkin lymphoma, or plasma cell neoplasms, and severe or ...
1. In a retrospective review of over 1500 Hodgkin lymphoma (HL) survivors, the risk of coronary heart disease (CHD) was ...
1. In this study, patients who received treatment for Hodgkin’s Lymphoma had a 3 to 6 fold increased incidence of ...
1. In patients with negative PET scans after 3 cycles of chemotherapy, 3-year progression free survival was slightly better among ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.